Disclosed herein are formulations, methods, and kits of formulations for inhibiting, ameliorating, delaying the onset of, reducing the likelihood of, treating, and/or preventing metabolic syndrome, and/or increasing energy levels. The formulations have at least one extract from a tart cherry, at least one antioxidant vitamin, at least one polyphenolic compound, and at least one prebiotic. Also disclosed are methods of making the formulations.

An affordable, palatable, maintainable and clinically-useful UC diet, characterized by a low content of sulfur, heme animal-based protein, taurine, animal-saturated fat.

A formulation for providing hydration and nutritional components to a subject includes from about 1,000 mg/serving to about 7,000 mg/serving of trimethylglycine, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable precursor thereof; from about 1 mg/serving to about 4,000 mg/serving of beta-hydroxybutyric acid or a pharmaceutically acceptable salt thereof; an electrolyte salt; optionally a purine nucleotide; and optionally a carbohydrate. The formulation may be an orally administered liquid including an aqueous carrier in an amount sufficient to provide a total volume/serving of about 2 oz. to about 32 oz.

The present application discloses a simple process for the purification of neutral human milk oligosaccharides (HMOs) produced by microbial fermentation. The process uses a combination of cationic ion exchanger treatment, an anionic ion exchanger treatment, and a nanofiltration and/or electrodialysis step, which allows efficient purification of large quantities of neutral HMOs at high purity. Contrary to the purification currently used in fermentative production of neutral HMOs, the presented process allows the provision of HMOs without the need of a chromatographic separation. The so purified HMOs may be obtained in solid form by spray drying, as crystalline material or as sterile filtered concentrate. The provided HMOs are free of proteins and recombinant material originating from the used recombinant microbial strains and thus very well-suited for use in food, medical food and feed (e.g. pet food) applications.

The present invention relates to infant formulas and follow-on formulas containing optimised amino acid profiles, in particular optimised amounts and/or ratios of phenylalanine. The formulas may contain intact proteins, hydrolysed proteins, protein fractions, free amino acids and/or a combination thereof selected based on their ability to provide the formula with an optimised amino acid profile. The present invention also relates to the administration of these formulas to infants in order to achieve balanced growth and/or development, for promoting, assisting or achieving balanced growth or development of the brain of an infant and/or the cognitive function of an infant, and may also assist in preventing or reducing the risk of obesity later in life.

Disclosed herein is a supplement comprising a probiotic, one or more gelling agents, and a sweetener and methods for manufacture thereof, wherein the sweetener is a low glycemic index sweetener that provides a sugar content that permits the probiotic to live and thrive within the supplement without dramatically increasing blood sugar level upon consumption of supplement. The presence of a living and thriving probiotic culture within the supplement further contributes to extended shelf stability and overall lifetime of the supplement.

The present invention relates to a composition in powder form comprising probiotic bacteria and at least one iron source selected from ferrous citrate, ferric citrate, ferrous sulphate monohydrate and mixtures thereof. Ferrous citrate, ferric citrate, ferrous sulphate monohydrate and mixtures thereof advantageously do not cause significant inhibition or reduction in the viability of the bacteria and thus these iron sources are advantageously used to fortify a composition in powder form comprising probiotic bacteria.

The present invention relates to a composition in powder form comprising probiotic bacteria and at least one iron source selected from ferrous citrate, ferric citrate, ferrous sulphate monohydrate and mixtures thereof. Ferrous citrate, ferric citrate, ferrous sulphate monohydrate and mixtures thereof advantageously do not cause significant inhibition or reduction in the viability of the bacteria and thus these iron sources are advantageously used to fortify a composition in powder form comprising probiotic bacteria.

Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.

An early in life nutritional intervention with a lipid component having both large lipid globules with phospholipids and an increased amount of palmitic acid in the sn-2 position in triglycerides were found to improve the fatty acid composition of cell membranes, in particular brain membranes.